Study of RT023 for advanced solid tumors
Part of Cancer clinical trials.
This study tests an experimental drug called RT023 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find out if RT023 is safe and effective, and what dose is best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of advanced solid tumor cancer that has spread or cannot be removed by surgery.
- You must be well enough to carry out light daily activities (ECOG 0 or 1).
- Your doctor expects you to live at least 12 weeks.
- You must have at least one tumor that can be measured on imaging (unless you are in the dose-escalation part of the study).
- You must not have untreated or active brain metastases, uncontrolled high blood pressure, or certain lung conditions.
- You must not have had an organ or stem cell transplant, or have HIV infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called RT036 for people with advanced solid tumors. The goal is to find a safe dose and see if it helps shrink or control the cancer.
This trial tests a new experimental medicine called SGT003 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the medicine is safe, how the body handles it, and whether it can shrink tumors or slow their growth.
This trial tests a new drug called BT02 for people with advanced solid tumors who have not had any cancer treatment before. It aims to see if BT02 is safe and how well it works.
This trial tests an experimental drug called MHB046C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
This trial is testing whether a new drug called CT7439 can help people with advanced solid tumors that have not responded to other treatments. It is a phase 1/2 study that also checks the drug's safety and how well it works.
This early-phase trial tests a new oral targeted drug, ND-003, for people with advanced solid tumors that have not responded to standard therapy. The study focuses on tumors with specific gene changes (NTRK or RET fusions), especially in the second part, to see if the drug can shrink tumors and be safe.
Hear when a new Advanced Malignant Solid Tumours trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.